Stock A166480 CORESTEMCHEMON INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CORESTEMCHEMON Inc.

Equities

A166480

KR7166480004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
11,650 KRW +0.09% Intraday chart for CORESTEMCHEMON Inc. -1.10% +72.08%
Mar. 26 CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. CI
Mar. 22 CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 188,609 142,243 364,645 293,575 255,403 144,945
Enterprise Value (EV) 1 149,475 108,337 291,318 252,467 271,246 175,009
P/E ratio -55.5 x -27.5 x -15.7 x -28.8 x -14 x -8.09 x
Yield - - - - - -
Capitalization / Revenue 8.45 x 5.86 x 13.8 x 9.71 x 5.52 x 4.31 x
EV / Revenue 6.7 x 4.46 x 11.1 x 8.35 x 5.86 x 5.2 x
EV / EBITDA -76.9 x -55.2 x -83.5 x -37.9 x -192 x -11.8 x
EV / FCF -48.4 x -27.1 x 7.61 x -7.81 x -6.4 x -15.7 x
FCF Yield -2.06% -3.68% 13.1% -12.8% -15.6% -6.37%
Price to Book 3.03 x 2.47 x 8.83 x 7.89 x 4.01 x 7.42 x
Nbr of stocks (in thousands) 15,717 15,717 15,717 15,869 32,870 21,410
Reference price 2 12,000 9,050 23,200 18,500 7,770 6,770
Announcement Date 3/21/19 3/19/20 3/18/21 3/17/22 3/23/23 3/21/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 22,317 24,284 26,358 30,240 46,293 33,657
EBITDA 1 -1,943 -1,962 -3,491 -6,664 -1,413 -14,826
EBIT 1 -4,021 -5,088 -6,998 -10,550 -6,013 -19,713
Operating Margin -18.02% -20.95% -26.55% -34.89% -12.99% -58.57%
Earnings before Tax (EBT) 1 -2,989 -3,481 -18,011 -4,425 3,705 -17,676
Net income 1 -3,397 -5,168 -23,187 -6,999 -2,657 -17,672
Net margin -15.22% -21.28% -87.97% -23.14% -5.74% -52.5%
EPS 2 -216.1 -329.0 -1,475 -642.5 -555.7 -837.0
Free Cash Flow 1 -3,086 -3,992 38,303 -32,330 -42,415 -11,152
FCF margin -13.83% -16.44% 145.32% -106.91% -91.62% -33.13%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/21/19 3/19/20 3/18/21 3/17/22 3/23/23 3/21/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 15,844 30,064
Net Cash position 1 39,134 33,906 73,327 41,109 - -
Leverage (Debt/EBITDA) - - - - -11.21 x -2.028 x
Free Cash Flow 1 -3,086 -3,992 38,303 -32,330 -42,415 -11,152
ROE (net income / shareholders' equity) -3.88% -5.74% -31.5% -7.51% 1.87% -60.7%
ROA (Net income/ Total Assets) -2.79% -3.64% -3.83% -4.72% -3.5% -15.8%
Assets 1 121,632 142,126 605,726 148,226 76,014 111,624
Book Value Per Share 2 3,960 3,671 2,627 2,344 1,937 913.0
Cash Flow per Share 2 284.0 192.0 2,155 372.0 98.10 105.0
Capex 1 3,062 3,815 4,997 15,043 9,078 9,174
Capex / Sales 13.72% 15.71% 18.96% 49.75% 19.61% 27.26%
Announcement Date 3/21/19 3/19/20 3/18/21 3/17/22 3/23/23 3/21/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CORESTEMCHEMON INC. Stock CORESTEMCHEMON Inc.
+72.08% 182M
MODERNA, INC. Stock Moderna, Inc.
+25.71% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.44% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.14% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.35% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.20% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.43% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.17% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A166480 Stock
  4. Financials CORESTEMCHEMON Inc.